Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
复制标题
二羟基蒽二酮 (DHAD) 与阿糖胞苷 (Ara-C) 组合的毒性评估。
DOI：
10.1007/bf00169979
复制
发表时间：
1987
影响因子：
3.4
通讯作者：
Vietti,TJ
中科院分区：
文献类型：
--
作者：
Steuber,CP;Land,VJ;Civin,CI;Ragab,AH;Krischer,J;Vietti,TJ
为了确定最佳剂量，给予二羟基蒽二酮（DHAD），每天一次，剂量水平为6，7，8，10 mg/m2，连续3天，联合连续7天输注阿糖胞苷（Ara-C）。20名接受这些药物治疗的白血病儿童中有19名出现发热，需要住院治疗。有4人死亡，其中2人因确诊感染而死亡。1例患者发生非致死性心脏毒性。未观察到其他显著毒性。20例患者中有7例出现缓解。当与Ara-C联合给药时，推荐的DHAD剂量为8 mg/m2/天。
To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m2/day when given in combination with Ara-C.